Guardant Health Reaches New 52-Week High of $145.75

Guardant Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 145.75 on June 25, 2026. This achievement marks a remarkable performance for the company, which operates within the Pharmaceuticals & Biotechnology sector. Over the past year, Guardant Health has demonstrated an impressive growth trajectory, with a staggering 375.52% increase in its stock price, significantly outpacing the S&P 500's performance of 20.77%. With a market capitalization of USD 11,098 million, Guardant Health is classified as a mid-cap company. Despite being loss-making, the firm showcases a remarkable return on equity of 413.71%, indicating strong efficiency in generating profits from its equity base. However, the company does not offer a dividend yield, and its debt-to-equity ratio stands at -3.32, reflecting a unique financial structure. The stock's previous 52-week low was recorded at USD 40.36, highlighting the substantial growth it has achieved over the past year. This upward trend underscores the evolving dynamics within the biotechnology sector and the company's position within it.